Recent next-step advances in cancer immunology are found on many frontiers: on targeting cancer and cancer niches with specific conjugated or unconjugated monoclonal antibodies, by activating immune responses via monoclonal antibodies, antigens and vaccines, cytokines, costimulatory pathways, and checkpoint modulators, or by adoptive cell transfer, comprising the newly approved CAR T biomedicines, and many combinatorial strategies for an increasing number of sub-indications. The field has quickly carved out a new 50-billion-dollar biologics industry that is expected to double again in only 4-5 years.
Conventional cancer treatments are still the most practiced and the most canonical therapies of today`s medical anti-cancer strategies. They comprise surgery, chemotherapy, and radiation therapy, while cancer immunotherapy is still the new approach that is further becoming further becoming increasingly accepted and has only recently been innovated and approved. In early 2018, approximately 32 monoclonal antibodies were approved by the FDA or EMA for cancer immunotherapy for a cancer indication and medical purpose. There are more than 10,000 clinical studies linked to these 32 medicinal products of the biologics type, which are registered at the NIH and at the NIH database.
In 2016, immunotherapy treatments captured 33% of spending on oncology drugs, despite accounting for just 9% of FDA-approved oncology drugs. All the large oncology drug companies are building robust immunotherapy pipelines, driving increased M&A and investor interest.
Based on therapy, the market is fragmented into monoclonal antibodies, vaccines, checkpoint inhibitors, cell therapies, immune system modulators, adoptive cell transfer, cytokines, and others. The monoclonal antibodies segment generated revenue of USD 32.57 billion in 2020. The market is expected to grow at a CAGR of 10.29% during the forecast period to reach a market valuation of USD 65.13 billion by 2027F owing to the diverse set of clinically relevant mechanisms of action like directly targeting tumor cells while simultaneously promoting the induction of long-lasting anti-tumor immune responses.
Based on the application, the market is fragmented into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head and neck cancer, other cancer applications. The lung segment dominated the market and generated revenue of USD 22.26 billion in 2020. However, breast cancer is anticipated to grow at the highest CAGR during the forecast period and reach USD 36.10 billion by 2027F.
The cancer immunotherapies are available at various centres including Cancer specialty/research centres and hospitals & clinics. The cancer specialty/research centres are anticipated to dominate the market during the analyzed period and reach USD 111.65 billion by 2027F. Also, the segment is expected to grow at the highest CAGR throughout the forecast period 2021-2027F.
For a better understanding of the market adoption of the Cancer Immunotherapy market, the market is analyzed based on its worldwide presence in the countries such as North America (United States and Canada), Europe (Germany, France, Italy, Spain, United Kingdom and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World. North America constitutes a major market for the Cancer Immunotherapy industry and generated revenue of USD 37.56 billion in 2020 owing to the increasing incidence of cancer, and rising healthcare spending in the region.
Some of the major players operating in the market include AbbVie, Amgen, AstraZeneca, bluebird bio, Bristol-Myers Squibb, F. Hoffmann-La Roche, Janssen Biotech, Merck, Novartis, and Pfizer. Several M&A's along with partnerships have been undertaken by these players to develop Cancer Immunotherapy.
The global Cancer Immunotherapy market was valued at USD 87.40 billion in 2020 and is projected to expand significantly with a CAGR of 10.25% from 2021-2027F. The market is expected to witness a boost on Increasing patient pool and higher mortality rate are augmenting the need for cancer immunotherapy globally.
Conventional cancer treatments are still the most practiced and the most canonical therapies of today`s medical anti-cancer strategies. They comprise surgery, chemotherapy, and radiation therapy, while cancer immunotherapy is emerging as the new approach that is further being increasingly accepted and has only recently been innovated and approved. In early 2018, approximately 32 monoclonal antibodies were approved by the FDA or EMA for cancer immunotherapy for a cancer indication and medical purpose. The surging cancer incidence and rising geriatric population is anticipated to boost the market growth. In 2020, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) will be diagnosed worldwide, with almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer). Female breast cancer has surpassed lung cancer as the most diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung (11.4%), colorectal (10.0%), prostate (7.3%), and stomach (5.6%) cancers.
According to a study titled as "Estimation of the Percentage of US Patients with Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs" conducted in 2019 by Alyson Haslam and Vinay Prasad, the estimated percentage of eligible cancer patients in the United States for checkpoint inhibitor drugs was 1.54% in 2011 and increased to an estimated 26.86% by 2015 and 43.63% in 2018. Furthermore, NSCLC (21.48%), hepatocellular carcinoma (4.95%), and SCLC were the diseases that contributed the most to the eligibility calculation (3.79%). In 2016, immunotherapy treatments captured 33% of spending on oncology drugs, despite accounting for just 9% of FDA-approved oncology drugs. All the large oncology drug companies are building robust immunotherapy pipelines, driving increased M&A and investor interest. Several cancer immunotherapies such as monoclonal antibodies have the diverse set of clinically relevant mechanisms of action like directly targeting tumor cells while simultaneously promoting the induction of long-lasting anti-tumor immune responses. During the outbreak of COVID-19, several cancer patients worldwide had experienced long-lasting city lockdown and delay of immunotherapies. For instance, in China treatment showed that the delay of three to four months might have mild, if any, influence on the efficacy of immunotherapy for patients with well-controlled disease.
AbbVie, Amgen, AstraZeneca, bluebird bio, Bristol-Myers Squibb, F. Hoffmann-La Roche, Janssen Biotech, Merck, Novartis, and Pfizer are some of the prominent players operating in the global Cancer Immunotherapy market. Several M&A's along with partnerships have been undertaken by these players to facilitate costumers with hi-tech and innovative products.
Insights Presented in the Report
"Amongst therapy, monoclonal antibodies segment holds the major share"
Based on the therapy type, the market is fragmented into monoclonal antibodies, vaccines, checkpoint inhibitors, cell therapies, immune system modulators, adoptive cell transfer, cytokines, and others. The monoclonal antibodies segment dominated the market with a share of 37.3% in 2020 and is expected to maintain its dominance during the forecast period owing to the diverse set of clinically relevant mechanisms of action.
"Amongst application, breast cancer is anticipated to grow at the highest CAGR during the analyzed period"
Further based on application, the market is fragmented into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head and neck cancer, other cancer applications. In 2020, lung cancer accounted for a maximum market revenue share of 25.5% and is expected to remain dominant during the analyzed period. However, the breast segment is anticipated to grow at the highest CAGR over the forecast period and reach market evaluation of USD 36.10 million by the end of forecast year. Breast cancer accounts 1 in 4 cancer cases and 1 in 6 in cancer mortality.
Amongst end-user, cancer specialty/research centers segment holds the major share"
Based on the end-user type, the market is fragmented into Cancer Specialty/Research Centers and hospitals and clinics. The cancer specialty/research centers dominated the market in 2020 with revenue of USD 55.43 billion and is anticipated to maintain its dominance during the analyzed period. Furthermore, the segment is also expected to grow at the highest CAGR during the period.
"North America signifies one of the largest markets of Cancer Immunotherapy Market"
For a better understanding of the market dynamics of the Cancer Immunotherapy market, a detailed analysis was conducted for different regions across the globe including North America (United States, Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of APAC), Rest of World has been conducted. North America dominated the market and generated revenue of USD 37.56 billion in 2020. In America, nearly 1.9 million new cancer cases are expected to be diagnosed in 2021. Approximately 608,570 Americans are expected to die of cancer in 2021, which translates to about 1,670 deaths per day. Cancer is the second most common cause of death in the US, exceeded only by heart disease.
Reasons to buy this report:
? The study includes market sizing and forecasting analysis validated by authenticated key industry experts
? The report presents a quick review of overall industry performance at one glance
? The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments
? Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry
? The study comprehensively covers the market across different segments
? Deep dive regional level analysis of the industry
Customization Options:
The Cancer Immunotherapy Market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.
Table of Contents
1 MARKET INTRODUCTION
1.1 Market Definitions
1.2 Objective of the Study
1.3 Limitation
1.4 Stake Holders
1.5 Currency Used in Report
1.6 Scope of the Global Cancer Immunotherapy Market Study
2 RESEARCH METHODOLOGY OR ASSUMPTION
2.1 Research Methodology for the Global Cancer Immunotherapy Market
2.1.1 Main Objective of the Global Cancer Immunotherapy Market
3 MARKET SYNOPSIS
4 EXECUTIVE SUMMARY
5 TOP START-UPS UNDER CANCER IMMUNOTHERAPY SECTOR
6 CANCER IMMUNOTHERAPY AMID COVID-19
7 GLOBAL CANCER IMMUNOTHERAPY MARKET REVENUE (USD BN), 2019-2027F
8 MARKET INSIGHTS BY THERAPY
8.1 Monoclonal Antibodies
8.2 Vaccines
8.3 Checkpoint Inhibitors
8.4 Cell Therapies
8.5 Immune System Modulators
8.6 Adoptive Cell Transfer
8.7 Cytokines
8.8 Others
9 MARKET INSIGHTS BY APPLICATION
9.1 Lung Cancer
9.2 Breast Cancer
9.3 Colorectal Cancer
9.4 Melanoma
9.5 Prostate Cancer
9.6 Head and Neck Cancer
9.7 Other Cancer Applications
10 MARKET INSIGHTS BY END-USER
10.1 Cancer Specialty/Research Centers
10.2 Hospitals & Clinics
11 MARKET INSIGHTS BY REGION
11.1 North America Cancer Immunotherapy Market
11.1.1 United States
11.1.2 Canada
11.2 Europe Cancer Immunotherapy Market
11.2.1 Germany
11.2.2 France
11.2.3 United Kingdom
11.2.4 Italy
11.2.5 Spain
11.2.6 Rest of Europe
11.3 Asia Pacific Cancer Immunotherapy Market
11.3.1 China
11.3.2 Japan
11.3.3 India
11.3.4 Australia
11.3.5 Rest of Asia Pacific
11.4 Rest of World Cancer Immunotherapy Market
12 CANCER IMMUNOTHERAPY MARKET DYNAMICS
12.1 Market Drivers
12.2 Market Challenges
12.3 Impact Analysis
13 CANCER IMMUNOTHERAPY MARKET OPPORTUNITIES
14 CANCER IMMUNOTHERAPY MARKET TRENDS
15 LEGAL & REGULATORY FRAMEWORK
16 DEMAND AND SUPPLY SIDE ANALYSIS
16.1 Demand Side Analysis
16.2 Supply Side Analysis
16.2.1 Top Product Launches
16.2.2 Top Business Partnerships
16.2.3 Top Business Expansions, Investments and Divestitures
16.2.4 Top Merger and Acquisitions
17 VALUE CHAIN ANALYSIS
18 COMPETITIVE SCENARIO
18.1 Porter's Five Forces Analysis
18.1.1 Bargaining power of Supplier
18.1.2 Bargaining power of Buyer
18.1.3 Industry Rivalry
18.1.4 Availability of Substitute
18.1.5 Threat of new Entrants
18.2 Competitive Landscape
18.2.1 Company Shares, By Revenue
19
AbbVie
Amgen
AstraZeneca
bluebird bio
Bristol-Myers Squibb
F. Hoffmann-La Roche
Janssen Biotech
Merck
Novartis
and Pfizer